Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)
NCT02595944Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2016
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Arm I (nivolumab) with Arm II (observation) (2 arms). Primary endpoints: Disease-Free Survival up to 10 years and Overall Survival up to 10 years. Started Jul 2016; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02595944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595944.